CN107827848B - 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 - Google Patents
一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 Download PDFInfo
- Publication number
- CN107827848B CN107827848B CN201711043501.8A CN201711043501A CN107827848B CN 107827848 B CN107827848 B CN 107827848B CN 201711043501 A CN201711043501 A CN 201711043501A CN 107827848 B CN107827848 B CN 107827848B
- Authority
- CN
- China
- Prior art keywords
- andrographolide
- phase
- culture medium
- ethyl acetate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004405 cytokine-induced killer cell Anatomy 0.000 title claims abstract description 19
- 238000001727 in vivo Methods 0.000 title claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 8
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title abstract description 73
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title abstract description 70
- 238000002360 preparation method Methods 0.000 title abstract description 28
- 230000002147 killing effect Effects 0.000 title abstract description 11
- 239000000126 substance Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 231100000225 lethality Toxicity 0.000 claims 1
- 238000000855 fermentation Methods 0.000 abstract description 34
- 230000004151 fermentation Effects 0.000 abstract description 34
- 239000000047 product Substances 0.000 abstract description 27
- 239000012084 conversion product Substances 0.000 abstract description 24
- 230000009466 transformation Effects 0.000 abstract description 24
- 239000002608 ionic liquid Substances 0.000 abstract description 20
- 230000000813 microbial effect Effects 0.000 abstract description 16
- 238000012258 culturing Methods 0.000 abstract description 14
- 238000000746 purification Methods 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 238000011426 transformation method Methods 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 78
- 239000000243 solution Substances 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 239000002904 solvent Substances 0.000 description 53
- 238000000926 separation method Methods 0.000 description 43
- -1 ethyl acetate-ethanol-water-formic acid Chemical group 0.000 description 33
- 238000010262 high-speed countercurrent chromatography Methods 0.000 description 33
- 238000009630 liquid culture Methods 0.000 description 33
- 230000005526 G1 to G0 transition Effects 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- 238000002156 mixing Methods 0.000 description 20
- 238000005086 pumping Methods 0.000 description 20
- 239000012488 sample solution Substances 0.000 description 20
- 241000235555 Cunninghamella Species 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 229930003451 Vitamin B1 Natural products 0.000 description 11
- 238000009835 boiling Methods 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000002024 ethyl acetate extract Substances 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 235000013575 mashed potatoes Nutrition 0.000 description 11
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 11
- 235000019796 monopotassium phosphate Nutrition 0.000 description 11
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 11
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 11
- 239000004810 polytetrafluoroethylene Substances 0.000 description 11
- 238000000967 suction filtration Methods 0.000 description 11
- 229960003495 thiamine Drugs 0.000 description 11
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 11
- 239000011691 vitamin B1 Substances 0.000 description 11
- 235000010374 vitamin B1 Nutrition 0.000 description 11
- 238000007872 degassing Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000009210 therapy by ultrasound Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 5
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 4
- 239000012964 benzotriazole Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YIIRVUDGRKEWBV-FZOOCBFYSA-N (3e)-3-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]furan-2-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/C=COC1=O YIIRVUDGRKEWBV-FZOOCBFYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XMJAJFVLHDIEHF-UHFFFAOYSA-N 14-deoxy-11, 12-didehydroandrographolide Natural products OCC1(C)C(O)CCC2(C)C1CCC(=C)C2C=CC1=CCOC1=O XMJAJFVLHDIEHF-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- XMJAJFVLHDIEHF-YSDSKTICSA-N dehydroandrographolide Natural products C([C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=CC1=CCOC1=O XMJAJFVLHDIEHF-YSDSKTICSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
存活率(%) | 占对照组肿瘤重量百分比(%) | |
对照组 | 20 | / |
CIK细胞组 | 65 | 58.8 |
CIK细胞加氧化穿心莲内酯组 | 95 | 25.7 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711043501.8A CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711043501.8A CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107827848A CN107827848A (zh) | 2018-03-23 |
CN107827848B true CN107827848B (zh) | 2021-06-11 |
Family
ID=61650252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711043501.8A Active CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107827848B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110367244B (zh) * | 2019-08-10 | 2021-09-24 | 广东创晟控股集团有限公司 | 乌药醚内酯用于制备外周血单个核细胞冻存保护剂的用途 |
CN113321631B (zh) * | 2020-08-13 | 2022-02-01 | 云南西力生物技术股份有限公司 | 双穿心莲内酯g及其制备方法和在药物上的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101200465A (zh) * | 2006-12-11 | 2008-06-18 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7902359B2 (en) * | 2006-12-11 | 2011-03-08 | Hutchison Medipharma Enterprises Limited | Decahydronaphthalene compounds |
-
2017
- 2017-10-31 CN CN201711043501.8A patent/CN107827848B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101200465A (zh) * | 2006-12-11 | 2008-06-18 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
Oxidation studies on Andrographolidey;VIJAYAVITTHAL T. MATHAD et al.;《Natural Product Research》;20061031;第20卷(第12期);1053-1058 * |
Also Published As
Publication number | Publication date |
---|---|
CN107827848A (zh) | 2018-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102911138B (zh) | 一种褐藻中岩藻黄素的提取纯化方法 | |
CN107827848B (zh) | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 | |
CN102690283B (zh) | 一种从鸡蛋蛋黄中提取卵磷脂的方法 | |
CN110407847B (zh) | 一种从土曲霉中获得的azaphilones类化合物及其制备和应用 | |
CN109970538A (zh) | 一类海洋真菌来源的二倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN110863021B (zh) | 一种细胞松弛素类化合物的制备方法和应用 | |
CN107188797A (zh) | 一种从海洋球石藻中提取棕榈酸的方法 | |
CN101367716B (zh) | 一类炭壳菌聚酮及其制法和用途 | |
CN108689851A (zh) | 一类惕各烷型二萜化合物及其制备方法和应用 | |
CN104523792B (zh) | 一种富含强心苷的马利筋乳汁提取物及其制备方法与应用 | |
CN112795617B (zh) | 海洋真菌次级代谢物及其制备与应用 | |
CN110330544A (zh) | 一种4,4,1-双环甾类化合物及其制备方法和用途 | |
CN107141198A (zh) | 一种从海洋球石藻中提取叶绿醇的方法 | |
CN107151218A (zh) | 一种从海洋球石藻中提取邻苯二甲酸二丁酯的方法 | |
CN107200684A (zh) | 一种从海洋球石藻中提取肉豆蔻酸的方法 | |
CN108017554A (zh) | 一种从海洋球石藻中提取神经酰胺的方法 | |
CN101481379A (zh) | 银杏内生真菌菌株发酵液的乙酸乙酯萃取物中分离的化合物 | |
CN111732579B (zh) | 一种聚醚聚酮类化合物polydecalinmycin及其制备方法和应用 | |
CN115215902B (zh) | 一种具有抗炎活性的水溶性红色食用真菌色素及其制备方法和用途 | |
CN109929006B (zh) | 阿魏菇中麦角甾醇过氧化物的提取方法及应用 | |
CN102093187A (zh) | 聚酮类化合物及其应用 | |
CN102633616B (zh) | 蒽醌二聚体衍生物Alterporriol P及其制备方法与应用 | |
CN105884782B (zh) | 一种吲哚二酮哌嗪类化合物的制备方法 | |
CN108186627B (zh) | 化合物helicascolide A在制备抗肿瘤药物中的应用 | |
CN107523593B (zh) | 一种微生物发酵制备脱水穿心莲内酯的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210527 Address after: Room 801, 238 JIANGCHANG Third Road, Jing'an District, Shanghai 200040 Applicant after: SHANGHAI TAOSHU BIOTECHNOLOGY Co.,Ltd. Address before: 211198 1009 Tianyuan East Road, Gao Xin Garden, Jiangning District, Nanjing, Jiangsu. Applicant before: NANJING XUHANG BIOLOGICAL MATERIAL TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oxidized andrographolide, preparation method and application of enhancing the lethality of CIK cells in vivo Effective date of registration: 20220901 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231122 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for preparing oxidized andrographolide and its application in enhancing the in vivo killing power of CIK cells Effective date of registration: 20231221 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2023310000902 |